直近一年間の累計
アクセス数 : ?
ダウンロード数 : ?
ID 119253
著者
北村, 直也 Kochi University
Sento, Shinya Kochi University
Yoshizawa, Yasumasa Kochi University
Sasabe, Eri Kochi University
Yamamoto, Tetsuya Kochi University
キーワード
head and neck squamous cell carcinoma
molecular targeted therapy
cetuximab
immune checkpoint inhibitor
multi-oncogene panel test
photoimmunotherapy
資料タイプ
学術雑誌論文
抄録
In recent years, advances in drug therapy for head and neck squamous cell carcinoma (HNSCC) have progressed rapidly. In addition to cytotoxic anti-cancer agents such as platinum-based drug (cisplatin and carboplatin) and taxane-based drugs (docetaxel and paclitaxel), epidermal growth factor receptor-tyrosine kinase inhibitors (cetuximab) and immune checkpoint inhibitors such as anti-programmed cell death-1 (PD-1) antibodies (nivolumab and pembrolizumab) have come to be used. The importance of anti-cancer drug therapy is increasing year by year. Therefore, we summarize clinical trials of molecular targeted therapy and biomarkers in HNSCC from previous studies. Here we show the current trends and future prospects of molecular targeted therapy in HNSCC.
掲載誌名
International Journal of Molecular Sciences
ISSN
14220067
出版者
MDPI
22
1
開始ページ
240
発行日
2020-12-29
権利情報
This article is an open access article distributed under the terms and conditions of the Creative Commons Attribution (CC BY) license (https://creativecommons.org/licenses/by/4.0/).
EDB ID
出版社版DOI
出版社版URL
フルテキストファイル
言語
eng
著者版フラグ
出版社版
部局
歯学系